Company
Company Information
History
Access
R&D
Technology
Technology Platform
NJA-730
Napa9-SPG
Business Development
Drug Discovery and Development Collaboration
Licensing Opportunity
News
Press release
Academic
Contact
HOME
»
news
news
December 2022
October 2020
January 2020
November 2019
September 2019
August 2019
July 2019
June 2019
March 2019
January 2019
December 2018
November 2018
June 2018
May 2018
February 2018
December 2016
April 2016
February 2014
NapaJen Pharma, Co., Ltd. initiates Phase 1 study of NJA-730, an RNAi therapeutic with a Unique Delivery Technology
ページトップ
Page Top
